Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 2 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus XARELTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 2 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus XARELTO.
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs XARELTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, accelerating its inhibition of coagulation factors IIa (thrombin), Xa, and others, thereby preventing thrombus formation and extension.
Direct factor Xa inhibitor that selectively blocks the active site of factor Xa, inhibiting thrombin generation and thrombus formation.
25,000 units in 250 mL D5W (100 units/mL) continuous IV infusion at 20,000-40,000 units/24 hours; adjust based on aPTT.
15 mg orally twice daily for 21 days, then 20 mg orally once daily; for atrial fibrillation: 20 mg orally once daily with food; for VTE prophylaxis in hip or knee replacement: 10 mg orally once daily.
None Documented
None Documented
30-150 minutes (dose-dependent, saturable); mean 60-90 min. Prolonged in hepatic/renal impairment and pulmonary embolism.
Terminal elimination half-life: 5–9 hours in young adults, 11–13 hours in elderly (≥65 years). Clinical context: Twice-daily dosing due to relatively short half-life; renal impairment prolongs half-life (up to 15 hours in severe impairment).
Primarily renal (40-60% as unchanged drug) and reticuloendothelial system; small amount biliary/fecal. Clearance is saturable.
Renal (36% as unchanged drug, 30% as inactive metabolites), fecal/biliary (33% as unchanged drug via hepatobiliary route). Total clearance is 10 L/h.
Category A/B
Category C
Anticoagulant
Anticoagulant